NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · page 16 of 25
The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.
Pitch deck · competitive_analysis · compare_peers · balanced density
Slide locked Sign in to view
Slide schematic 3/3
image 1/1 table 1/1 title 1/1
Components 3
illustration data headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1